The still under-investigated role of cognitive deficits in PML diagnosis

about

The still under-investigated role of cognitive deficits in PML diagnosis

Item

http://www.wikidata.org/entity/Q58864832

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2017

@uk

name

The still under-investigated role of cognitive deficits in PML diagnosis

@en

The still under-investigated role of cognitive deficits in PML diagnosis

@nl

type

Item

label

The still under-investigated role of cognitive deficits in PML diagnosis

@en

The still under-investigated role of cognitive deficits in PML diagnosis

@nl

prefLabel

The still under-investigated role of cognitive deficits in PML diagnosis

@en

The still under-investigated role of cognitive deficits in PML diagnosis

@nl

P1476

The still under-investigated role of cognitive deficits in PML diagnosis

@en

P2093

Cristina Scarpazza

http://www.w3.org/2001/XMLSchema#string

Flavia Mattioli

http://www.w3.org/2001/XMLSchema#string

Lucia Moiola

http://www.w3.org/2001/XMLSchema#string

Mirco Cosottini

http://www.w3.org/2001/XMLSchema#string

Nicola De Rossi

http://www.w3.org/2001/XMLSchema#string

Ruggero Capra

http://www.w3.org/2001/XMLSchema#string

Simonetta Gerevini

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring

Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

Neurological immune reconstitution inflammatory response: riding the tide of immune recovery

Cognitive impairment in multiple sclerosis

Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study

PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis.

P2888

s40893-016-0018-7

P31

scholarly article

P356

10.1186/S40893-016-0018-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1025300848

http://www.w3.org/2001/XMLSchema#string

P921

diagnosis